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Abstract
Purpose of Review The population of HIV-exposed uninfected (HEU) children is expanding rapidly, and over one million HEU
infants are born each year globally. Several recent studies have reported that HEU children, particularly in low- and middle-
income countries, are at risk of poor outcomes, including impaired growth and neurodevelopment. However, the reasons for poor
clinical outcomes amongst HEU children remain unclear.
Recent Findings We summarise the findings from recent large studies that have characterised growth and neurodevelopment in
HEU children, identified risk factors and explored underlying mechanistic pathways. We propose a conceptual framework to
explain how exposure to HIVand antiretroviral therapy (ART) may lead to adverse growth and neurodevelopment in uninfected
children, and review the available evidence and research gaps.
Summary We propose that HEU children are affected both indirectly, through the augmentation of universal risk factors under-
lying poor growth and neurodevelopment, and directly through HIV/ART-specific pathways, which ultimately may converge
through a series of common pathogenic mechanisms. In the era of universal ART, a better understanding of these pathways is
crucial to inform future prevention and intervention strategies.
Keywords HIV-exposed uninfected . Child . Growth . Stunting . Early child development
Introduction
Globally, approximately 1.4 million HIV-infected pregnant
women give birth each year [1, 2]. The increased coverage
of antiretroviral therapy (ART) for pregnant and breastfeeding
women through prevention of mother-to-child transmission
(PMTCT) programs has dramatically reduced perinatal and
postnatal HIV transmission. Correspondingly, the global pop-
ulation of HIV-exposed uninfected (HEU) children is increas-
ing and, in 2017, was estimated to have reached 14.8 million
[3]. This number will continue to increase with improved
PMTCT coverage as over one million HEU children are born
every year, the majority of whom are now also exposed to
ART [3–5]. Emerging data showing poorer health outcomes
of HEU compared to HIV-unexposed children [6] means there
is a pressing need to understand and address the mechanisms
underlying compromised outcomes.
The Sustainable Development Goals have focused atten-
tion on the importance of healthy growth and develop-
ment, so that children can thrive as well as survive. The
in utero period and first 2 years after birth (the first
1000 days) represent a highly sensitive period of develop-
ment, during which substantial physical growth, including
brain maturation, occurs [7]. Early fetal exposures are
recognised to have long-term consequences for the child
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and future adult. Given the number of children exposed to
HIV and ART in utero, it is important to understand the
effects of these exposures. This review will first explore
growth and development in HEU children; second, outline
a conceptual framework to highlight the pathways through
which HIV exposure may impact growth and development;
and third, examine how this may help to inform preven-
tion and intervention strategies.
Studies of HIV-Exposed Uninfected Children
Over recent decades, there has been a growing number of
studies evaluating the outcomes of HEU children.
However, interpretation of studies can be challenging for
several reasons. First, the effects of HIV exposure may
differ between high-income and low-income settings.
The epidemiology of HIV infection in high-income set-
tings, where adult infections are often found in popula-
tions with more substance use and mental health disor-
ders, differs from the more generalised epidemic in sub-
Saharan Africa. In addition, HEU children vary in terms
of duration of exposure to both HIV (prenatal/postnatal)
and ART and are exposed to different antiretroviral drug
classes and combinations. This may mean mechanisms
differ across countries. Second, studies are often limited
by a lack of comparable HIV-unexposed control groups,
particularly due to differences in breastfeeding and socio-
economic status. Third, studies have often been small in
size without adequate HIV testing of included children to
rule out HIV infection. Fourth, there has been a lack of
standardised definitions of outcomes. Despite these limita-
tions, it is possible to draw conclusions on health outcomes
from large, well-conducted studies, many of which have
clearly demonstrated that HEU children have higher
mortality than HIV-unexposed children [6, 8–11], pre-
dominantly driven by increased frequency and severity
of common childhood infections, particularly respiratory
disease [6, 8, 9, 12–15]. Recent meta-analyses estimate
twofold higher child mortality amongst HEU compared
to HIV-unexposed children in the first 1–2 years after
birth, with a similar risk persisting in children between 2 and
5 years of age [10, 11]. Finally, a clear divide in the
categorisation of studies comes from the use of ART.
Studies from the pre-ART era have the benefit of explor-
ing the effect of HIV exposure without the potential con-
founding effects of ART. However, they may be less rel-
evant in the modern era where most HEU children are
also ART-exposed. Although there are clear benefits from
ART in reducing HIV transmission and improving mater-
nal health, there is the potential for ART to have negative
effects on the developing fetus, and separating the effects
of HIV and ART exposure is challenging.
Growth and Neurodevelopment of HEU
Children
An estimated 250 million (43%) children under the age of
5 years fail to reach their developmental potential in low-
and middle-income countries (LMIC), based on proxy mea-
sures of stunting and poverty [16••]. Impaired growth and
development have far-reaching consequences across the life-
course, impacting academic outcomes, employment and long-
term non-communicable disease risk, as well as intergenera-
tional effects on health and human capital (Fig. 1). Emerging
data indicate that this cycle may be critically influenced by
HIV exposure.
Growth Outcomes
Linear growth is an important reflection of overall child
wellbeing. In the largest cohort to date, Zimbabwean HEU
children in the pre-ART era had 23% more stunting (length-
for-age Z score < − 2) than HIV-unexposed children from the
same communities by 12 months of age [17]. The effect of
HIV exposure on growth in the ART era is less clear because
there have been few studies to date. Reducing antenatal HIV
exposure through ART control of maternal viraemia during
pregnancy decreases the risk of transmission and may have
additional benefits for HEU infants. However, intrauterine
growth restriction and preterm birth have been associated with
certain antiretroviral drugs in some studies [18•]. Findings
from two large cohorts in the ART era have recently been
reported in two different African settings. In Cape Town,
where overall stunting prevalence was low, HEU children
Fig. 1 The cycle of child growth and development
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had lower length-for-age Z scores and almost threefold more
stunting than HIV-unexposed children [19•]. In rural
Zimbabwe, where overall stunting prevalence was high,
HEU children also had lower length-for-age Z scores and al-
most twice as much stunting [20]. Similar findings were seen
for weight-for-age, underweight (weight-for-age Z score < −
2) , head ci rcumference and microcephaly (head
circumference-for-age Z- score < − 2), although not weight-
for-length or wasting (weight-for-length Z score < − 2) [20].
Collectively, these studies indicate that growth impairment
continues to be a major problem amongst HEU children in
the current PMTCT era.
Neurodevelopmental Outcomes
The negative impact of HIV infection on child brain develop-
ment, both clinically and neuroradiologically, is well-
established [21, 22]. There is increasing evidence that HIV
exposure (without infection) may also be associated with
neurodevelopmental impairment, although the manifestations
are more subtle than for HIV-infected children [21, 23, 24••].
Studies from LMIC settings report an impact of HIVexposure
on language [21–23, 24••, 25, 26], behaviour [21, 23], cogni-
tion [24••, 26] and motor function [24••, 27], although there
are limitations to these studies: most were from the pre-ART
era, had small sample sizes and lacked adequate comparator
groups. A large Zimbabwean study from the pre-ART era
found that head circumference was consistently lower in
HEU compared to HIV-unexposed infants throughout the first
year after birth [28], but there were no neurodevelopmental
evaluations in this cohort.
Recent studies in sub-Saharan Africa have generally sup-
ported findings from the pre-ART era. One study of South
African HEU children aged 12 months found increased odds
of cognitive (OR 2.28, 95% CI 1.13, 4.60) and motor delay
(OR 2.10, 95% CI 1.03, 4.28) [29•], while another from
Botswana showed increased expressive language delay
(aOR 1.44, 95% CI 1.01, 2.06) at 2 years [30]. HEU children
aged 2 years in rural Zimbabwe had poorer motor and lan-
guage development compared to their HIV-unexposed com-
munity counterparts [31] and the Drakenstein Child Health
Study found receptive and expressive language delay in
South African HEU children compared to HIV-unexposed
children at 2 years of age [32•].
In contrast, a recent study fromUganda andMalawi did not
find any neurodevelopmental differences in HEU children
aged 1 to 5 years compared to an HIV-unexposed group
[33•]. Similarly, evidence from HEU children in high-
income settings has generally been reassuring [34, 35].
However, some language delay has been reported [36, 37]
and there is a suggestion that cognition and behaviour may
be affected at older ages [21, 23] [38]. A UK study found
similar outcomes for HIV-infected adolescents and their
uninfected siblings, and that both groups were impaired com-
pared to normative data [39]. There are few studies of older
HEU children in LMIC settings from the current ART era.
One multisite study across five African countries did not find
any cognitive differences compared to HIV-unexposed chil-
dren [40], although language skills were not reported. Other
studies have indicated potential ongoing delays, including
poorer school mathematics performance in Zambia [41], and
lower IQ, language and fine motor development in HEU chil-
dren aged 2–12 years in Thailand and Cambodia [26].
Overall, although further research is needed, current evi-
dence suggests HEU children may be at risk of delayed
neurodevelopment in the early years of life, particularly in
LMIC settings, and there are concerns regarding later school
and behavioural outcomes.
Pathogenesis—Universal Pathways Versus
HIV-Specific Pathways?
We hypothesise that there are two broad pathways through
which HIV exposure without infection may impact child
growth and development: (1) indirectly, by augmenting
existing universal pathways that are known common risk fac-
tors for poor growth and development; and (2) directly, via
HIV-specific mechanisms including exposure to HIV virions,
immune activation and ART toxicity (Fig. 2).
Augmentation of Universal Pathways
Growth and development entail the interaction of genetically
determined biological processes and environmental influ-
ences. The ecological model of development [42] describes
the interacting nature of these internal and external factors
over time. Both the cumulative burden and timing of these
risks likely influence neurodevelopment [43]. Research sug-
gests that HIVexposure may augment a range of universal risk
factors, and below, we outline the available evidence.
Intrauterine Infections
Many in utero infections have consequences for the de-
veloping fetus. Cytomegalovirus (CMV), rubella, Zika
virus, syphilis and toxoplasmosis have all been docu-
mented to impact child development [44]. HIV-infected
mothers are at increased risk for some of these infections;
several studies, although not all, have indicated that
CMV in particular may be more prevalent in HIV-
affected mothers and children [45•, 46] and may explain
some of the adverse outcomes associated with HIV expo-
sure [47].
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Toxins
Exposure to alcohol, tobacco and recreational drugs has a
dose-related impact on child growth and development [48,
49]. This is potentially through direct toxicity, augmentation
of inflammatory upregulation, as well as poorer maternal
health-seeking and parenting behaviour. HIV infection in
adults is associated with an accentuated risk of alcohol and
substance use in many settings [34]. Air pollution and envi-
ronmental toxins (such as mycotoxins) are also potential risk
factors for poor child growth [50, 51]. There is some evidence
that HIV-infected individuals may have higher mycotoxin
levels despite the same exposure when compared to HIV-
uninfected controls. This may be due to impaired liver func-
tion resulting in a decreased ability to detoxify metabolites,
though not all reports have corroborated this finding [52, 53].
Mycotoxin exposure may plausibly exacerbate several path-
ways underlying HIV pathogenesis (including enteropathy
and micronutrient deficiencies), thereby affecting early
growth [54]. Additionally, the interacting effects of air pollut-
ants and HIV have been associated with adverse birth out-
comes, potentially through increasing nitric oxide levels [51].
Adverse Birth Outcomes
Prematurity and small-for-gestational age (SGA) are consis-
tently associated with poor postnatal growth and development
[55, 56]. Premature infants are vulnerable to prolonged
hospitalisation and are at greater risk for neonatal infection
and sepsis [57]. HIV-exposed children are at increased risk
of prematurity, SGA and low birth weight [58], which are
major risk factors for stunting [59]. Evidence suggests that
HIVexposure remains associated with adverse birth outcomes
and neonatal death despite maternal ART [60, 61]. Separately,
ART exposure has been associated with adverse birth out-
comes. A recent meta-analysis found that HIV-positive wom-
en who conceived on ART had 41% greater risk of preterm
delivery compared to HIV-positive women who started ART
during pregnancy [18••]. A study from Botswana showed this
risk is similar between efavirenz- and dolutegravir-containing
regimens [62]; however, recent concerns have been raised
around the safety of dolutegravir at the time of conception
due to a potential increase in neural tube defects [63].
Further data on the impact of specific drugs and the relation-
ship between poor birth outcomes and timing of ART initia-
tion are urgently needed.
Breastfeeding Practices
Global recommendations are that breastfeeding should be ear-
ly (initiated within 1 h of birth), exclusive (breastmilk and
prescribed medications only for the first 6 months of life)
and prolonged (through 2 years of age). Suboptimal
breastfeeding increases morbidity and mortality, particularly
in LMIC settings [64]. A review of 17 observational studies
demonstrated that better cognitive outcomes were associated
with optimal breastfeeding practices [65]. Findings from a
2015 analysis of the 1982 Pelotas birth cohort in Brazil also
reported a dose–response association between breastfeeding
duration and increased child cognitive performance, educa-
tional attainment and income at the age of 30 years [66].
Globally, guidance on infant feeding for HIV-positive mothers
in LMIC settings has changed over time with the introduction
of PMTCT and recognition of the benefits of breastfeeding,
despite the risk of postnatal HIV transmission [67]. However,
formula feeding to prevent postnatal HIV transmission
through breastmilk means that HEU children continue to have
lower rates of breastfeeding across the world, which may
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influence developmental outcomes. The impact of postnatal
ART exposure through breastfeeding is still to be examined.
Inadequate Diet
Food insecurity in pregnancy is a risk factor for adverse birth
outcomes and, during early childhood, has been associated
with poor growth and neurodevelopment arising from com-
plex mechanisms including nutritional insufficiencies and in-
creased parental stress [68]. Children need sufficient nutrients
for growth and immune development, and dietary diversity is
necessary for optimal child outcomes. Food insecurity often
coexists with HIV infection [69] and has been found to be
associated with lower ART adherence, increased HIV-
associated illness and decreased survival in HIV-infected in-
dividuals [70].
Childhood Illness
Illnesses such as childhood pneumonia are associated with
long-term physical sequelae [71]. If hospitalisation is needed,
this may also have considerable impact on children and their
families [72], causing separation from parents and reducing
school attendance. Mounting evidence suggests HEU children
have increased infectious morbidity [6, 15, 73], and studies to
date have found this is particularly due to viral and bacterial
respiratory infections [14, 74, 75] in early life. There is also
evidence that HEU children are at risk for unusual infections
[76], including Pneumocystis jirovecii [9, 77–82], CMV [79,
83, 84] and haemorrhagic varicella [12, 77]. Correspondingly,
cohort studies from both LMIC and high-income settings sug-
gest HEU children have a higher risk of hospitalisation during
infancy [85–87] as well as elevatedmortality [10]. In pre-ART
era Zimbabwe, morbidity and mortality of HEU children were
strongly associated with maternal HIV disease severity, and
increased infectious morbidity amongst HEU children
remained until maternal CD4 counts were ≥ 800 cells/μL
[88]. In the ART era, a recent study from Belgium found that
initiation of maternal ART prior to pregnancy (i.e. conception
occurred on ART) appeared protective against infectious mor-
bidity in HEU children; however, further work is needed to
explore these findings in LMIC [86].
Maternal Illness and Death
Maternal physical health before and after birth critically influ-
ences child growth and development. Mothers who are unwell
may be less able to bond with and care for their children and
maternal undernutrition is a risk factor for adverse birth out-
comes [59, 89]. Furthermore, the loss of one or more parents,
orphanhood and institutionalisation have severe repercussions
[90]. There is extensive literature from the pre-ARTera on the
impact of parental death from HIV/AIDS, and it is estimated
over 17 million children have lost one/both parents from the
HIV/AIDS epidemic [90]. Parental death may affect children
emotionally and impact subsequent relationships. Maternal
death is itself related to outcomes of HEU infants [91], poten-
tially for several reasons. First, an infant born to a mother with
advanced disease may have greater immune abnormalities;
second, mothers who are sick in the late stages of their illness
may be unable to care for their children adequately, both phys-
ically and emotionally; and third, children who lose their
mothers may be subject to extreme poverty and homelessness
[92]. Even in the ART era, maternal HIV infection is associ-
ated with higher morbidity and mortality, and disease severity
inHIV-infectedmothers has been associatedwith infant health
outcomes [93].
Maternal Mental Health
Maternal psychological illness is linked to adverse child
health outcomes. Maternal depression is a risk factor for im-
paired child growth and development [94, 95]. Similarly, ma-
ternal stress has been found to have long-term repercussions
on child psychological health [96]. In many communities,
there is an association between maternal stress or depression
and HIV [97], and the additional exposure to maternal mental
health problems has been associated with risk of poor cogni-
tive development in HEU children [98]. Maternal capabilities,
which reflect the attributes required to care for a child, may be
affected by HIV infection. HIV-infected parents who are un-
well may be at risk of poverty because of an inability to work,
which may affect availability of food and access to healthcare
for the household. HEU children may be expected to take on
caregiver roles for infected family members or may be
neglected when other children in the family are HIV-infected
[39]. Using models to approximate the effect of maternal HIV
on young children in LMIC settings, it has been estimated
that, in HIV-affected families, school completion falls from
61 to 57%, and children have a 10% higher incidence of anx-
iety or depression than HIV-unexposed children [99–102].
HIV-Specific Pathways
Children born to HIV-infected mothers may be exposed to
both HIVand ART antenatally, perinatally and/or postnatally.
It is likely that in addition to the universal pathways discussed
above, there are separate HIV-related mechanisms that impact
on the child’s growth and development including (i) directly
through exposure to HIV virions, (ii) through effects of ma-
ternal immune activation/inflammation on the in utero envi-
ronment, (iii) by promoting immune activation/inflammation
in the fetus and/or child and (iv) via ART toxicity throughout
the period of in utero development and breastfeeding.
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Direct Exposure to HIV Virions and Viral Proteins
HIV is a neurotropic virus, which can cause encephalopathy in
HIV-infected infants, leading to microcephaly and
neurodevelopmental impairment [21]. Neuropathology occurs
directly, following exposure to HIV proteins that exhibit neu-
rotoxicity, and indirectly via microglial activation and neuro-
inflammation. It is conceivable that antenatal exposure to HIV
may affect brain development even without infection. Studies
have detected HIV-specific immune responses in HEU chil-
dren, suggesting that sufficient HIV antigen exposure occurs
antenatally or perinatally to prime immune responses [103].
Direct exposure of the fetal brain to HIV virions and proteins
may therefore be hypothesised to cause HIV-mediated neuro-
toxicity and impact brain growth and development. It is pos-
sible that in utero exposure to HIV virions may also modulate
immune responses, resulting in adverse outcomes, similar to
other chronic maternal infections including malaria, as
discussed below [103].
Maternal Immune Activation/Inflammation
A healthy, regulated immune system is important for
neurodevelopment [104]; therefore, HIV-related maternal im-
mune activation and chronic systemic inflammation may im-
pact fetal development. Advanced maternal HIV disease an-
tenatally, which is driven by immune activation, has been
consistently associated with HEU child morbidity [86]. Le
Roux and colleagues recently found that the duration and se-
verity of HIV viraemia in mothers during the antenatal period
was closely related to developmental outcomes in their HEU
infants, but immune activation was not assessed in this study
[105]. Dysregulated immune mechanisms have been linked to
various neurological disorders, and epidemiological associa-
tions exist between infections in pregnancy, maternal immune
activation and schizophrenia, autism and epilepsy in offspring
[106, 107], suggesting biological plausibility for this hypoth-
esis in the setting of HIV. Further studies of HIV-positive
mothers and HEU offspring are required in order to evaluate
associations between inflammation in pregnancy and child
development outcomes in these critical early years.
Immune Activation/Inflammation in the HIV-Exposed
Uninfected Child
Immune activation and inflammation have been demonstrated
in HIV-exposed fetuses and infants [108] which may trigger
cytokine release, directly impacting cell migration and axonal
growth and overall brain development [109–111, 112••].
Similarly, growth hormone axis disruption of Zimbabwean
HEU children has been associated with systemic immune ac-
tivation and the level of CMV replication [113]; inflammation
in these infants was predominantly driven by higher HIV viral
loads inmothers transmitting CMV [46]. Taken together, there
appears to be a complex relationship between maternal HIV
viraemia, early-life CMV acquisition, infant immune activa-
tion and the growth hormone axis, which may plausibly con-
tribute to poor linear and brain growth in HEU children, and
subsequent impaired neurodevelopment. Immune activation
and inflammation may also drive neurodevelopmental impair-
ment directly by impacting cell migration and axonal growth
via proinflammatory cytokines [112••].
ART Toxicity
Antiretrovirals cross the placental barrier with varying con-
centrations, and their potential effects on offspring growth
and development continue to be investigated [114]. It is chal-
lenging to disentangle the effects of HIVandART, particularly
because treatment improvesmaternal health, whichmay offset
any negative impact. Although ART is clearly essential both
for maternal health and to reduce vertical transmission of HIV,
exposure has been associated with adverse outcomes in some
studies [25], including prematurity, poor growth, metabolic
disturbance [115–117] and mitochondrial abnormalities
[118–120]. Other studies have found no serious adverse ef-
fects [121, 122]. The Pediatric HIV/AIDS Cohort study
(PHACS) has established the Surveillance Monitoring for
ART Toxicities in HEU children (SMARTT) study to monitor
for ART toxicities across a range ofmetabolic, growth, cardiac
and neurological outcomes [123, 124]. Results indicate little
adverse effect of maternal ART on child outcomes [35]; how-
ever, atazanavir has been found to potentially impact language
acquisition [25, 35, 36, 125], and tenofovir has been associat-
ed with an adverse impact on bone mineral content [126].
Recently, concerns have been raised over neural tube defects
following dolutegravir exposure at conception [127•].
Children may additionally be exposed to ART via breast milk
or directly as prophylaxis. Transient haematological alter-
ations, including anaemia, have been associated with zidovu-
dine exposure [128]. Further pharmacovigilance is needed to
document the long-term safety of individual antiretroviral
drugs and treatment combinations [108].
Mechanistic Pathways Mediating Impaired Growth
and Development
Universal andHIV-specific risk factors may drive poor growth
and neurodevelopment through a common set of mechanistic
pathways, as outlined in Fig. 2, including co-infections, in-
flammation, enteropathy, anaemia, nutrient deficiencies, epi-
genetic modifications and toxic stress, ultimately impacting
brain development. However, we lack data on many of these
pathogenic processes, meaning studies are needed to further
our understanding of the pathways within this conceptual
framework. Here, we provide some insights that support these
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mechanisms as potential mediators of the risk factors
discussed above.
Direct exposure to opportunistic infections may cause neu-
rotoxicity and impair growth. Congenital CMV infection in
particular has been shown to have a profound impact on
neurodevelopment, and the outcomes and mechanisms have
been reviewed comprehensively elsewhere [129]. CMV ac-
quisition in early life is very common in sub-Saharan Africa.
The impact of CMVon growth and development may be even
greater in HEU children and has recently been reviewed [45•].
Garcia-Knight and colleagues found that CMV viral load in
early infancy was negatively associated with weight-for-age
and head circumference-for-age Z scores in both HIV-exposed
and HIV-unexposed children in rural Kenya [130], and
Gompels and colleagues found that CMVwas associated with
growth and early child development in Zambia, particularly
amongst those exposed to HIV [47].
Environmental enteric dysfunction (EED) is an almost
ubiquitous subclinical disorder of the small intestine in
LMIC. EED is characterised by villous atrophy, impaired
gut barrier function, intestinal inflammation and microbial
translocation, leading to systemic inflammation [131]. We
have previously hypothesised that EED may be more severe
amongst HEU compared to HIV-unexposed children [132],
although a study of Zimbabwean infants at 6 weeks and
6 months of age showed similar levels of intestinal fatty acid
binding protein (I-FABP), a marker of enterocyte damage, in
HEU and HIV-unexposed infants. However, CRP was consis-
tently higher in HEU compared to HIV-unexposed infants,
highlighting that systemic inflammation is greater in the set-
ting of HIV exposure, although the drivers of inflammation
remain poorly defined [133]. Proinflammatory cytokines ap-
pear to be upregulated in HEU compared to HIV-unexposed
children even at birth, and certain brain maturation processes
such as cell migration and axonal growth may be particularly
vulnerable to this inflammatory milieu [111].
A common co-morbidity with stunting is iron deficiency
anaemia (IDA). IDA is a major cause of neurodevelopmental
impairment [43] and has been identified as one of the leading
causes of years lived with disability in children [134]. HIV-
exposed children have a higher frequency of anaemia than
HIV-unexposed children [135, 136], plausibly driven by ex-
posure to the virus itself and/or exposure to ART [137]. HIV
infection is associated with other micronutrient deficiencies
[52], and similar effects may be seen in HEU children, al-
though data are currently lacking.
Early-life programming may be influenced by the in
utero environment, causing DNA methylation and gene
expression modifications [138]. These epigenetic modifica-
tions are now understood to have potential biological
impact across the lifespan, leading to the theory of the
developmental origins of health and disease and may
have intergenerational effects [139]. HIV infection has been
shown to lead to epigenome-wide differential DNA methyla-
tion in infected individuals [140]. Additionally, some
studies have indicated that maternal HIV infection is asso-
ciated with epigenetic modifications in neonates, and HIV
and ART-exposed children have been found to have
reduced DNA methylation in peripheral blood repetitive
elements which may have long-term implications [141].
Further work is needed to understand this area; however,
research into HIV-associated neurocognitive disorders
(HAND) in adults indicates a role for genetic and epige-
netic profiles in predicting vulnerability to the neurological
effects of the virus and ART side effects [142].
Children living in adverse environments are at risk of
chronic stress and persistent activation of their physiological
stress response—a process known as toxic stress
[143]. This process may act via the hypothalamic–pitui-
tary–adrenal (HPA) axis and immune responses to disrupt
healthy brain circuit development, particularly in the pre-
frontal cortex [144]. Through this impact on the
neuroendocrine–immune (NEI) network, early experiences
can fundamentally shape the developing brain architecture
[143]. Early mutual interactions and experiences between
children and key adults also shape the developing brain
architecture and affect the NEI network [143]. Maternal
physical and psychological illness coupled with a lack of
social support may impact on a mother’s ability to provide a
safe and secure physical and emotional environment for her
infant [145]. Similarly, growing up in an environment
with inadequate stimulation or few early learning opportu-
nities is associated with reduced cognitive development
[146]. Children growing up in families affected by HIV
may face multiple adversities that affect the parent–child
relationship including parental illness and death, mental
illness, and stress from emotional, financial and social
pressures [147].
Ultimately, the risk factors and mechanisms identified
here may modulate brain growth and network develop-
ment. In addition, there may be other risk factors and
mechanisms, including those as yet unknown, influencing
these children. The in utero period and early postnatal life
is a time of substantial brain growth, when extensive neu-
ral network development and maturation take place [7].
The developing brain during this time is particularly sen-
sitive to environmental influences [148]. Animal models
as well as human studies suggest that infection-induced
maternal immune activation impacts developing neural
circuits [106]. Studies have indicated that maternal im-
mune activation and induction of proinflammatory cyto-
kines affecting the microbiota–gut–brain axis or eliciting
the stress response through the HPA axis result in atypical
brain development of the fetus [107, 149, 150].
Neuroimaging study findings of HEU-associated white
matter microstructural changes early in life [110, 151]
Curr HIV/AIDS Rep
suggest abnormal brain development as a potential mech-
anism for impaired child outcomes.
Improving HEU Child Growth
and Developmental Outcomes
Healthy birth, growth and development form the foundations
for later school performance, employment opportunities and
long-term human capital and health. First and foremost, the
continued global focus on reducing the burden of antenatal
HIV infection is the key to eliminating HIV exposure in chil-
dren. However, given the expanding population of HEU chil-
dren, efforts that focus on prevention and intervention strate-
gies to reduce the burden of poor HEU child outcomes are also
needed [108].
Prevention
In order to develop successful prevention strategies, fur-
ther research is needed to understand the effects of HIV
exposure on child outcomes. Improved ART coverage in
recent years means that family and home environments
may be different to previous decades; infant feeding advice
has shifted over time and the impact of breastfeeding
patterns in this population is still being unravelled; chil-
dren are now more commonly exposed to ART in utero
and postnatally, and more women are conceiving on ART.
Studies examining the relative contributions of HIV-
related pathways to growth and developmental impairment
in the context of universal risk factors in the era of ART
are needed to inform and focus these strategies [93]. In
order to detect early adverse outcomes and intervene,
pharmacovigilance systems are needed to assess effects of
ART on the growing and developing child. This is partic-
ularly relevant with the introduction of new drugs and
regimens, and new approaches to prevent HIV infection
in pregnant and breastfeeding women using pre-exposure
prophylaxis (PrEP). The concerns raised over dolutegravir
safety at the time of conception provide lessons going
forward [63]. Evaluating the relative safety of different
ART regimens in pregnancy for HEU child growth, brain
health and development is critical.
Some studies suggest there may be a high-risk sub-
group within the HEU population vulnerable to adverse
outcomes. Studies have found interactions between HIV
exposure and preterm birth leading to poorer growth [19•]
and worse cognitive and motor outcomes [29•], and also
poorer outcomes in HEU children with CMV coinfection,
compared to those without [47]. Further evidence is needed
to define these high-risk subgroups, who may benefit
from targeted prevention strategies, particularly where re-
sources are limited. Initiating prevention before conception
to optimise the health of mothers and their families will likely
be most effective.
Intervention
Alongside the development of prevention policies, interven-
tion strategies are needed to identify and support HEU chil-
dren at risk of growth and developmental impairment to im-
prove long-term outcomes. Evidence from institutionalised
children suggests interventions need to be initiated early (be-
fore the age of 5 years) to reverse impairment during critical
periods of growth and development; however, the optimal
window of opportunity for HEU children remains unclear
[43].
Targeting the universal risk factors that impact growth and
development is a logical strategy, through improved
breastfeeding, adequate nutrition, support for maternal physi-
cal and psychosocial health, reducing exposure to toxins, pre-
vention and early treatment of childhood infections and reduc-
ing poverty. Integrating this with improved maternal ART
adherence throughout the period of pregnancy and
breastfeeding to ensure HIV viral suppression would also like-
ly contribute to improved outcomes amongst HEU children.
This may be delivered as integrated care through multisectoral
platforms targeting health, nutrition and education, involving
both the caregiver and the child to break the intergenerational
cycle, using approaches such as the UNICEF Nurturing Care
Framework.
Concurrently, research informing additional targeted inter-
ventions to address the HIV-related pathways by assessing
scalable packages of care for early child growth and develop-
ment are needed. Recently, the SHINE trial in rural Zimbabwe
demonstrated that the combination of improved infant and
young child feeding and improved water, sanitation and hy-
giene interventions resulted in better outcomes in both motor
and language development amongst HEU children [152].
Further work is required to examine the most effective, scal-
able intervention strategies moving forward.
Conclusions
There are currently 14.8 million HEU children worldwide and
this population continues to expand. Increasing evidence sug-
gests these children, particularly in LMIC settings, have a
disparity in growth and development compared to HIV-
unexposed children. Our conceptual framework highlights po-
tential pathways linking HIV and/or ART exposure and ad-
verse outcomes. We propose HEU children may be affected
by accentuating existing universal risk factor pathways as well
as through HIV-specific pathways, via final common patho-
genic mechanisms. Overall, a multifactorial causal pathway is
most likely to shape the growth and neurodevelopment of the
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HEU child. More research is critically needed in the era of
universal ART, to understand these pathways further and in-
form prevention and intervention strategies.
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